BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, in an oral communication at the 2023 Peripheral Nerve Society annual meeting (PNS-2023) held in Copenhagen from 17-20 June 2023.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause.

Ocean Biomedical, Inc. announced today that an equity analyst coverage report issued by Fundamental Research Corp. (“FRC”) has increased FRC’s price target of OCEA stock to $17.63 per share, up from FRC’s initial report in March 2023 of $16.40.

Virion Therapeutics, LLC today, presented data entitled “Intrahepatic CD8 + T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model” at the European Association for the Study of Liver Diseases (EASL) annual Congress.

MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).

Inhibikase Therapeutics, Inc. today announced a physician and patient awareness campaign for its Phase 2 ‘201' program evaluating IkT-148009 as a potentially disease-modifying treatment of Parkinson’s disease.

Quest Diagnostics today announced that it has completed its previously announced acquisition of Haystack Oncology.

CMP Pharma, Inc. announced today that Liqrev (Sildenafil) Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-made oral liquid of sildenafil, is now available.

GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of AREXVY (respiratory syncytial virus vaccine, adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older over multiple RSV seasons and after annual revaccination.

Biomerica Inc. announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system.